Read more
New for 2023. 1st February's virtual community meeting will feature a presentation and Q&A session on clinical trials. This is an opportunity to learn about the process of trials from initial ideas to completion and how and when patients can get involved. Read more
Researchers have used a GI device to show that oesophageal distensibility can help clarify the level of scarring in paediatric EoE. This could lead to earlier identification and more targeted intervention. Read more
A free online course to help different medical disciplines understand EoE has received full accreditation for Continuing Medical Education. Find out more and how to access it here. Read more
Dupilumab has been recommended for EU approval by the CHMP for the treatment of eosinophilic oesophagitis (EoE). It is the first biologic drug in the EU indicated for EoE for sufferers aged 12+. Read more
The third part of a trial investigating dupilumab in EoE has found the drug maintains its clinical, symptomatic and histologic efficacy and safety profile up to Week 52 in adults and children over 12+. Read more
October 2022 - MESSINA trial of Fasenra in EoE patients demonstrated a significant improvement in histological disease remission but not an improvement in dysphagia symptoms. Read more
An educational EoE Roadshow is coming to cities across the UK, offering an excellent opportunity for HCPs to learn more about the fast-changing landscape of eosinophilic oesophagitis. Read more
Enrolment has completed for a Phase 2 trial investigating an immune-resetting molecule in the treatment of EoE. The molecule can reset the immune system from a pro-inflammatory state to a regulated homeostatic state. Read more
The Index, produced by CEGIR researchers, is another step towards global consensus, and is designed to help HCPs monitor EoE severity to make informed decisions about treatment and management. Read more
July 2022 - A trial investigating dupilimab to treat children under 12 with EoE has achieved positive results. This follows the FDA's approval of dupilimab to treat EoE in adults and children 12 and over earlier this year. Read more
New Eosinophilic Oesophagitis EoE Paediatric to Adult Comprehensive Medical Diagnosis and Care Guidelines Read more
After many years of the USA having no approved treatment options for EoE. Approval for use has been announced for a new biologic injection. Read more
See what we have achieved so far and learn how you can support our vision of a world where everyone with an eosinophilic disease can eat without pain. We need your help. Read more
Learn what inspired EOS Network charity and how the founder's families experience gives the charity a true understanding of the challenges families face when living with Eosinophilic diseases Read more
We need our community to volunteer to distribute EoE information to their local doctor's surgeries. This will include a patient information poster for the waiting room and a GP information leaflet that will direct them to a dedicated GP online training module, guidelines and patient resources. Read more
The upcoming EoE Guidelines will be released and presented at the British Society for Gastroenterology BSG Live Annual Meeting from 22-23 June. EOS Network will be exhibiting at the event, alongside Guidelines committee chair Professor Anjan Dhar and other co-authors. Read more
Sean Goss is a professional footballer with EoE. His journey will be familiar to many living with the condition - adapting lifestyle and struggling to find a correct diagnosis. We're proud to have him as an ambassador for our charity. Read more
A Charter outlining the key rights and expectations for people living with eosinophil-associated diseases. It proposes four key principles that will patients should expect from the management of their conditions and set a basic standardisation of care. Read more
We are fundraising for our son Fergus and those like him who have been diagnosed with a rare Eosinophilic Gastrointestinal Disease. Our family relay team of 5 will be cycling 1363Km in 24 hours on two indoor bikes. Read more